Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Durvalumab |
Indication/Tumor Type | transitional cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | transitional cell carcinoma | predicted - sensitive | Durvalumab | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with Imfinzi (durvalumab) resulted in an overall response rate (ORR) of 17.8% (34/191) in advanced urothelial carcinoma patients with an ORR of 27.6% (27/98) in patients with high PD-L1 (CD274) expression and 5.1% (4/79) in patients with low or negative PD-L1 (CD274), and similar complete response rates between the two groups (PMID: 28817753; NCT01693562). | 28817753 |
PubMed Id | Reference Title | Details |
---|---|---|
(28817753) | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. | Full reference... |